Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siemens Healthcare Diagnostics

- PMLiVE

Pfizer shares positive late-stage results for RSV vaccine Abrysvo in high-risk adults

There are currently no vaccines approved for use in adults aged 18 to 59 years

- PMLiVE

Pfizer’s antibiotic combination receives CHMP recommendation to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Pfizer/Astellas’ Xtandi receives CHMP recommendation to treat recurrent prostate cancer

For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease

- PMLiVE

Revolutionising healthcare: The crucial role of diagnostics in transforming the NHS

Amid the formidable challenges faced by the NHS, Onyx Health delve into the pivotal role of diagnostics in healthcare transformation, showcasing how collaboration, innovation, and patient-centric approaches are revolutionising healthcare...

Onyx Health

- PMLiVE

Pfizer’s 20-valent pneumococcal vaccine receives EC approval for infants and children

The 20 serotypes included in Prevenar 20 cause the majority of circulating pneumococcal disease

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

- PMLiVE

Pfizer’s Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis

The immune-mediated inflammatory bowel disease affects approximately 300,000 people in the UK

- PMLiVE

Pfizer’s RSV vaccine Abrysvo shown to maintain strong efficacy in older adults

RSV infections account for up to 160,000 hospitalisations among older adults each year in the US

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

- PMLiVE

Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Mtech Access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links